Get the Stockscreener App
24.28
3.76%
0.88
After Hours:
24.28
Septerna Inc stock is traded at $24.28, with a volume of 3.95M.
It is up +3.76% in the last 24 hours and up +7.91% over the past month.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.
See More
Previous Close:
$23.40
Open:
$23.4
24h Volume:
3.95M
Relative Volume:
19.96
Market Cap:
$1.08B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+8.44%
1M Performance:
+7.91%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$20.61
$24.69
1-Week Range:
$20.61
$24.69
52-Week Range:
$18.62
$27.47
Septerna Inc Stock (SEPN) Company Profile
Compare SEPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
24.28 | 1.08B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-19-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-19-24 | Initiated | JP Morgan | Overweight |
| Nov-19-24 | Initiated | TD Cowen | Buy |
| Nov-19-24 | Initiated | Wells Fargo | Overweight |
Septerna Inc Stock (SEPN) Latest News
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
Vertex Global reports ten IPOs, acquisitions worldwide in 2024 - Tech in Asia
Septerna, Inc.’s (NASDAQ:SEPN) Quiet Period Set To Expire on December 4th - Defense World
New MRGPRX2 antagonists disclosed in Septurna patent - BioWorld Online
Cantor Fitzgerald Weighs in on Septerna FY2024 Earnings - Defense World
Analysts Offer Predictions for Septerna FY2024 Earnings - MarketBeat
Septerna, Inc. Reports Q3 2024 Financials and Progress - Yahoo Finance
Septerna (NASDAQ:SEPN) Coverage Initiated at Wells Fargo & Company - Defense World
Cantor Fitzgerald Begins Coverage on Septerna (NASDAQ:SEPN) - Defense World
Septerna (NASDAQ:SEPN) Coverage Initiated at TD Cowen - Defense World
Septerna started by J.P. Morgan at overweight, GPCR platform cited - MSN
Septerna Inc. (SEPN) reports earnings - Quartz
Septerna proposes terms for upsized $175M IPO - MSN
Septerna Shares Fall 7% After Wider 3Q Loss - MarketWatch
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Septerna Advances Key Drug Trial, Reports $137.5M Cash Position After Successful IPO | SEPN Stock News - StockTitan
Septerna initiated with an Overweight at JPMorgan - Yahoo Finance
Cantor launches Septerna stock coverage, highlighting platform value and growth in GPCR drug development - Investing.com Nigeria
TD Cowen optimistic on Septerna stock as preclinical data fuels confidence - Investing.com Canada
JPMorgan bullish on Septerna stock—pipeline strategy drives optimism - Investing.com India
Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones - AOL
Septerna started by J.P. Morgan at overweight, GPCR platform cited (NASDAQ:SEPN) - Seeking Alpha
This Apollo Global Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Septerna (NASDAQ:SEPN) Coverage Initiated at Cantor Fitzgerald - MarketBeat
Septerna (NASDAQ:SEPN) Now Covered by TD Cowen - MarketBeat
Septerna (NASDAQ:SEPN) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - MarketBeat
Septerna (NASDAQ:SEPN) Earns Overweight Rating from Analysts at Wells Fargo & Company - MarketBeat
JPMorgan bullish on Septerna stock—pipeline strategy drives optimism By Investing.com - Investing.com Canada
RA Capital Management's Strategic Investment in Septerna Inc - GuruFocus.com
Buffett Still Building This Stake, Plus Huge Insider Buy in Biotech IPO - 24/7 Wall St.
Wednesday's Insider Activity: Top Buys and Sells in US Stocks By Investing.com - Investing.com Australia
Nasdaq debutante Septerna swells its IPO to $331m - pharmaphorum
Septerna (NASDAQ:SEPN) Files Amendment and Restatement of Certificate of Incorporation and Bylaws - Defense World
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering - ForexTV.com
Ra Capital Management buys $75 million in Septerna stock By Investing.com - Investing.com Australia
Ra Capital Management buys $75 million in Septerna stock - Investing.com
IPO Radar: Septerna, Swiggy and Horizon Robotics - The Armchair Trader
Septerna sees $11.7 million in stock purchases by Third Rock Ventures - Investing.com South Africa
IPO Roundup: Brazil Potash, Septerna and more (NYSEARCA:IPO) - Seeking Alpha
Sentiment for IPO Market in 2025 Continues to Improve - TheStreet
U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names - Seeking Alpha
Septerna’s GPCRs draw strong demand in $288M IPO - BioCentury
Finance Watch: Septerna Raises $288m In Public Market Debut - Citeline
Hedge Funds, Asset Managers Turn Dollar Bulls on Election Risks - Yahoo Finance
Septerna Shares Jump 19% After IPO Shows Biotech Still Hot - Bloomberg
Septerna Shares Rise 29% on First Trading Day - MarketWatch
Septerna’s Upsized IPO Brings In $288M to Support a Pipeline of GPCR Drugs - MedCity News
Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut - KFGO
Septerna Shares Jump 42% After IPO Shows Biotech Still Hot - AllSides
Septerna Inc Stock (SEPN) Financials Data
There is no financial data for Septerna Inc (SEPN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Septerna Inc Stock (SEPN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Third Rock Ventures V, L.P. | 10% Owner |
Oct 28 '24 |
Buy |
18.00 |
370,500 |
6,669,000 |
6,215,591 |
| Third Rock Ventures V, L.P. | 10% Owner |
Oct 28 '24 |
Buy |
18.00 |
279,500 |
5,031,000 |
3,152,456 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):